tetano
Editor, Senior Moderator
Front Endocrinol (Lausanne)
. 2022 Mar 18;13:840580.
doi: 10.3389/fendo.2022.840580. eCollection 2022.
A Case Series of Ketoacidosis After Coronavirus Disease 2019 Vaccination in Patients With Type 1 Diabetes
Fumiyoshi Yakou[SUP] 1 [/SUP], Masuo Saburi[SUP] 1 [/SUP], Ai Hirose[SUP] 1 [/SUP], Hiroaki Akaoka[SUP] 1 [/SUP], Yusuke Hirota[SUP] 1 [/SUP], Takaaki Kobayashi[SUP] 1 [/SUP], Naoko Awane[SUP] 1 [/SUP], Nobuteru Asahi[SUP] 1 [/SUP], Toshihiro Amagawa[SUP] 1 [/SUP], Sachihiko Ozawa[SUP] 2 [/SUP], Atsushi Ohno[SUP] 1 [/SUP], Takaya Matsushita[SUP] 1 [/SUP]
Affiliations
Abstract
Introduction: We report a case series of severe ketoacidosis after COVID-19 vaccination in a type 1 diabetes patients treated with insulin and an SGLT-2 inhibitor.
Case report: We present two cases of type 1 diabetes mellitus. One patient was treated with insulin therapy and an SGLT-2 inhibitor, and the other patient was treated with insulin therapy alone. Both patients became ill after coronavirus disease-2019 vaccination, making it difficult to continue their diet or insulin injections. On admission, they developed severe diabetic ketoacidosis. This is the first report of ketoacidosis after coronavirus disease-2019 vaccination.
Conclusion: The vaccine should be carefully administered to type 1 diabetes patients receiving intensive insulin therapy and a sodium-glucose transporter due to the high risk ketoacidosis. It is important to instruct patients to drink sufficient fluids and to continue insulin injections when they become sick.
Keywords: clinical diabetes; coronavirus disease 2019 vaccination; ketoacidosis; latent autoimmune diabetes in adults; sodium-glucose cotransporter 2 inhibitor; type 1 diabetes.
. 2022 Mar 18;13:840580.
doi: 10.3389/fendo.2022.840580. eCollection 2022.
A Case Series of Ketoacidosis After Coronavirus Disease 2019 Vaccination in Patients With Type 1 Diabetes
Fumiyoshi Yakou[SUP] 1 [/SUP], Masuo Saburi[SUP] 1 [/SUP], Ai Hirose[SUP] 1 [/SUP], Hiroaki Akaoka[SUP] 1 [/SUP], Yusuke Hirota[SUP] 1 [/SUP], Takaaki Kobayashi[SUP] 1 [/SUP], Naoko Awane[SUP] 1 [/SUP], Nobuteru Asahi[SUP] 1 [/SUP], Toshihiro Amagawa[SUP] 1 [/SUP], Sachihiko Ozawa[SUP] 2 [/SUP], Atsushi Ohno[SUP] 1 [/SUP], Takaya Matsushita[SUP] 1 [/SUP]
Affiliations
- PMID: 35370952
- PMCID: PMC8971718
- DOI: 10.3389/fendo.2022.840580
Abstract
Introduction: We report a case series of severe ketoacidosis after COVID-19 vaccination in a type 1 diabetes patients treated with insulin and an SGLT-2 inhibitor.
Case report: We present two cases of type 1 diabetes mellitus. One patient was treated with insulin therapy and an SGLT-2 inhibitor, and the other patient was treated with insulin therapy alone. Both patients became ill after coronavirus disease-2019 vaccination, making it difficult to continue their diet or insulin injections. On admission, they developed severe diabetic ketoacidosis. This is the first report of ketoacidosis after coronavirus disease-2019 vaccination.
Conclusion: The vaccine should be carefully administered to type 1 diabetes patients receiving intensive insulin therapy and a sodium-glucose transporter due to the high risk ketoacidosis. It is important to instruct patients to drink sufficient fluids and to continue insulin injections when they become sick.
Keywords: clinical diabetes; coronavirus disease 2019 vaccination; ketoacidosis; latent autoimmune diabetes in adults; sodium-glucose cotransporter 2 inhibitor; type 1 diabetes.